Year: 2021
Type: article
Abstract: advances in the biology of aging will be at the origin of therapeutical improvement making it possible to increase life expectancy in good health and prevent OA. Senescence and OA PhysiopathologySenescence is a complex pathophysiological phenomenon that can be observed in the context of tissue damage associated with aging in the context of cancer development.Cellular senescence is a cell Abstract OA is a large unmet medical need, with increasing incidence in our aging population.Recent physiopathogical knowledge have identified the accumulation of senolytic cells in cartilage and the synovium as deleterious.This has prompted the development of senolytic drugs in OA.Senolytics are a class of drugs that selectively clear senescent cells.Senolytics induce apoptosis of senescent cells accumulated in joint tissue with a tissue-destructive SASP (senescent associated secreted proteome).They include three major classes of molecules.Senolytics which seek to kill/eliminate senescent cells by playing on increased cell survival pathways during the senescence process.Seno-morphics, which change the inherent properties of the senescent state, for example by reactivating autophagy while maintaining the stopping of the cycle.And finally, a third class of therapeutic agents, senosuppressants, will block the entry or the spread of senescence.Thus, drugs with senotherapy properties such as metformin, rapamycin, fisetin, dasatinib, quercetin, resveratrol, have shown modulation of the aging process and associated pathologies including OA.Thus, many therapeutic alternatives in the treatment of osteoarthritis are opening up, but clinical trials will have to be carried out to confirm their effectiveness.
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4206091471
